Clinical trial • Phase I • Oncology
LY4066434 for Pancreatic ductal adenocarcinoma | Non-small cell lung cancer | Colorectal cancer | Advanced solid tumor | Metastatic solid tumor | KRAS-mutant solid tumor
Phase I trial of LY4066434 for Pancreatic ductal adenocarcinoma | Non-small cell lung cancer | Colorectal cancer | Advanced solid tumor | Metastatic solid…
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Pancreatic ductal adenocarcinoma | Non-small cell lung cancer | Colorectal cancer | Advanced solid tumor | Metastatic solid tumor | KRAS-mutant solid tumor
- Trial Stage
- Phase I
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 10-10-2024
- First CTIS Authorization Date
- 20-11-2024
Trial design
Phase I trial across 18 sites in Belgium, Spain, Germany and others.
- Target Sample Size
- 397
Recruitment
- Planned Sample Size
- 397
- Recruitment Window Months
- 59
Geography
- Total Number Of Sites
- 18
- Total Number Of Participants
- 353
Belgium
- Earliest CTIS Part Ii Submission Date
- 08-11-2024
- Latest Decision Or Authorization Date
- 24-02-2026
- Processing Time Days
- 473
- Number Of Sites
- 3
- Number Of Participants
- 33
Sites
- Site Name
- Cliniques Universitaires Saint-Luc
- Department Name
- Oncology
- Contact Person Name
- Rachel Galot
- Contact Person Email
- rachel.galot@saintluc.uclouvain.be
- Site Name
- Institut Jules Bordet
- Department Name
- Oncology
- Contact Person Name
- Nuria Kotecki
- Contact Person Email
- nuria.kotecki@hubruxelles.be
- Site Name
- Universitair Ziekenhuis Gent
- Department Name
- Oncology
- Contact Person Name
- Sylvie Rottey
- Contact Person Email
- sylvie.rottey@uzgent.be
Spain
- Earliest CTIS Part Ii Submission Date
- 22-04-2025
- Latest Decision Or Authorization Date
- 02-03-2026
- Processing Time Days
- 314
- Number Of Sites
- 7
- Number Of Participants
- 98
Sites
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Medical Oncology
- Contact Person Name
- Elena Garralda
- Contact Person Email
- egarralda@vhio.net
- Site Name
- Institut Catala D'oncologia
- Department Name
- Medical Oncology
- Contact Person Name
- Ramon Salazar
- Contact Person Email
- ramonsalazar@iconcologia.net
- Site Name
- Hospital Universitario Ramon Y Cajal
- Department Name
- Medical Oncology
- Contact Person Name
- Federico Longo
- Contact Person Email
- fedelongomunoz@hotmail.com
- Site Name
- Hospital Universitario 12 De Octubre
- Department Name
- Medical Oncology
- Contact Person Name
- Santiago Ponce
- Contact Person Email
- santiago.ponce@oncosur.org
- Site Name
- Hospital Universitario Regional De Malaga
- Department Name
- Medical Oncology
- Contact Person Name
- Julia Alcaide
- Contact Person Email
- drayulia@hotmail.com
- Site Name
- Hospital General Universitario Gregorio Maranon
- Department Name
- Medical Oncology
- Contact Person Name
- Antonio Calles
- Contact Person Email
- antonio.calles@salud.madrid.org
- Site Name
- Hospital Del Mar
- Department Name
- Medical Oncology
- Contact Person Name
- Edurne Arriola
- Contact Person Email
- earriola@parcdesalutmar.cat
Germany
- Earliest CTIS Part Ii Submission Date
- 11-04-2025
- Latest Decision Or Authorization Date
- 25-02-2026
- Processing Time Days
- 320
- Number Of Sites
- 5
- Number Of Participants
- 100
Sites
- Site Name
- Asklepios Kliniken Hamburg GmbH
- Department Name
- Onkologie und Palliativmedizin
- Contact Person Name
- Dirk Arnold
- Contact Person Email
- d.arnold@asklepios.com
- Site Name
- Universitaetsklinikum Wuerzburg AöR
- Department Name
- Interdisziplinäres Studienzentrum (ISZ) mit ECTU
- Contact Person Name
- Barbara Deschler-Baier
- Contact Person Email
- deschler_b@ukw.de
- Site Name
- Charite Universitaetsmedizin Berlin KöR
- Department Name
- Klinik für Hämatologie und Onkologie, ECTU
- Contact Person Name
- Damian Rieke
- Contact Person Email
- damian.rieke@charite.de
- Site Name
- SLK-Kliniken Heilbronn GmbH
- Department Name
- Medizinische Klinik III
- Contact Person Name
- Uwe Martens
- Contact Person Email
- uwe.martens@slk-kliniken.de
- Site Name
- Krankenhaus Nordwest GmbH
- Department Name
- Institut für Klinisch-Onkologische Forschung (IKF)
- Contact Person Name
- Thorsten Götze
- Contact Person Email
- goetze.thorsten@khnw.de
France
- Earliest CTIS Part Ii Submission Date
- 13-05-2025
- Latest Decision Or Authorization Date
- 24-02-2026
- Processing Time Days
- 287
- Number Of Sites
- 2
- Number Of Participants
- 72
Sites
- Site Name
- Institut Gustave Roussy
- Department Name
- DITEP Drug Development Department
- Contact Person Name
- Antoine Hollebecque
- Contact Person Email
- antoine.hollebecque@gustaveroussy.fr
- Site Name
- Centre Leon Berard
- Department Name
- Medical Oncology
- Contact Person Name
- Philippe Cassier
- Contact Person Email
- philippe.cassier@lyon.unicancer.fr
Italy
- Earliest CTIS Part Ii Submission Date
- 27-05-2025
- Latest Decision Or Authorization Date
- 06-03-2026
- Processing Time Days
- 283
- Number Of Sites
- 1
- Number Of Participants
- 50
Sites
- Site Name
- Centro Ricerche Cliniche Di Verona S.r.l.
- Department Name
- Oncology Unit
- Contact Person Name
- Davide Melisi
- Contact Person Email
- davide.melisi@univr.it
Sponsor
Primary sponsor
- Full Name
- Eli Lilly & Co.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- LY4066434
- Active Substance
- LY4066434
- Modality
- Small molecule
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)